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A rare complication in a child undergoing chemotherapy for acute
lymphoblastic leukemia: Superior sagittal sinus thrombosis
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Received June 7, 2010; accepted September 10, 2010AbstractWe report the case of a 4-year-old boy with acute lymphoblastic leukemia in high-risk group who suffered from generalized tonic-colonic
seizure evolving into status epilepticus, and subsequent left hemiparesis during his first reinduction chemotherapy, consisting of dexamethasone,
vincristine, L-asparaginase, and epirubicin. Superior sagittal sinus and cerebral venous thrombosis, predominantly in right side, were proved by
brain magnetic resonance imaging. After aggressive treatment with low-molecular weight heparin (LMWH), left hemiparesis improved in
1 week. And he was fully ambulatory 3 weeks later. The second cycle of reinduction chemotherapy was conducted smoothly with the
concomitant use of LMWH. This case illustrates the strong correlation of the rare thrombotic complication, superior sagittal sinus thrombosis,
and hypercoagulable status secondary to combination use of L-asparaginase and corticosteroid. Early and vigilant recognition of superior sagittal
sinus thrombosis and prompt anticoagulation with LMWH may prevent further neurological damage.
Copyright  2011 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Leukemia is the most common childhood malignancy
worldwide, and acute lymphoblastic leukemia (ALL)
comprises most pediatric leukemias. With risk-adapted inten-
sive chemotherapy, the cure rate of pediatric ALL approaches
nearly 80%. However, this intensive treatment may also bring
about a number of significant morbidities during chemotherapy
treatment. Thromboembolic events comprise a great number of
morbidities in ALL patients. Most of the thromboembolic
events are central venous catheter-related thrombosis. Superior
sagittal sinus thrombosis (SSST) is a rare complication. Here,
we report a case of SSST in a child undergoing his first rein-
duction chemotherapy for ALL. The correlation of SSST with* Corresponding author. Dr. Hsiu-Ju Yen, Department of Pediatrics, Taipei
Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan,
ROC.
E-mail address: hjyen2@vghtpe.gov.tw (H.-J. Yen).
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doi:10.1016/j.jcma.2011.01.041hypercoagulable status and underlying hyperlipidemia, and
treatment and prophylaxis of SSST are discussed here.
2. Case report
A 4-year-old boy was diagnosed with ALL at our hospital
with the initial presentations of productive cough and inter-
mittent high-grade fever for 2 weeks. His initial white blood
cell count was 64,490/mL, and bone marrow examination
revealed around 50% lymphoblasts, which were positive for
CD19 and CD10. Port-A central venous catheter was
implanted over left upper chest after diagnosis. He received
induction, consolidation, and continuation chemotherapy with
TPOG-ALL-2002 high-risk protocol without delay. Six
months after diagnosis, he started reinduction chemotherapy
(dexamethasone 8 mg/m2 on Days 1e8 and 15e21; epirubicin
30 mg/m2 on Days 1 and 8; vincristine 1.5 mg/m2 on Days 1,
8, and 15; L-asparaginase 5,000 ku/m2 every other day for nine
doses; triple intrathecal chemotherapy with methotrexatehinese Medical Association. All rights reserved.
Fig. 1. (A) Axial T2-weighted magnetic resonance imaging shows acute
infarction involving right anterolateral and parasagittal frontal lobe and some
foci of hemorrhage inside with “bright-up” on diffusion-weighted images. (B)
Coronal T1-weighted magnetic resonance imaging reveals low-attenuating
thrombus (arrow) within the superior sagittal sinus with “empty-delta” sign,
surrounded by a triangular area of enhancement.
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1). During this course of reinduction chemotherapy, only
mild skin rash developed after intramuscular injection of
L-asparaginase.
However, he developed generalized tonic-colonic seizure
attack lasting a few minutes soon after completion of the first
reinduction chemotherapy course. Furthermore, generalized
tonic-colonic seizure attacks took place and evolved into status
epilepticus. Left hemiparesis was noted after these episodes.
His parents reported that the patient has neither past history of
epilepsy or febrile convulsion, nor any family history of
hypercoagulable status. The patient did not have symptoms or
signs of acute infection. His activity and appetite was quite
well before the seizure.
His initial blood counts at our pediatric emergency
department were as follows: white blood cell 5,307/mm3 with
34% neutrophils, 40% lymphocytes, and 24% monocytes,
hemoglobin 9.2 g/dL, and platelet 153,000/mm3. Serum
electrolytes, biochemistry tests, prothrombin time, activated
partial thromboplastin time, and C-reactive protein were
within normal limits. The computed tomography revealed an
essentially normal brain. After admission, increased opening
pressure to 384 mmH2O was measured by lumbar puncture.
The glucose and protein levels in cerebrospinal fluid were 54
and 26.1 mg/dL. No leukocytes, but red blood cells (117/mm3)
were identified in cerebrospinal fluid. Because of clinical
suspicion of herpes simplex virus encephalitis, acyclovir and
intravenous immunoglobulin were prescribed. Meanwhile,
low-molecular weight heparin (LMWH, enoxaparin sodium,
Clexane; Aventis Intercontinental, Maisons-Alfort Cedex,
France) 1 mg/kg/dose twice daily was initiated for concern of
possible thrombosis secondary to hypercoagulable status after
combined use of L-asparaginase and dexamethasone. His
coagulation profile on the next day was as follows:
prothrombin time 10.9 seconds, activated partial thrombo-
plastin time 29.9 seconds, D-dimer 1.8 ug/mL, fibrinogen
307 mg/dL, cholesterol 152 mg/dL, and triglyceride (TG)
154 mg/dL. Electroencephalography showed diffuse cortical
dysfunction especially over right hemisphere. Brain magnetic
resonance imaging (MRI) on the next day showed some foci of
filling defect in the lumen of the superior sagittal sinus with
“empty-delta” sign on T2-weighted images (Fig. 1). SSST
with acute venous infarction in right anterolateral and para-
sagittal frontal regions of the brain were diagnosed.
After treatment with LMWH, mannitol, and antiepileptic
drugs, his left-side hemiparesis improved within 1 week after
hospitalization, and he was fully ambulatory 3 weeks later.
Further anticoagulation medication with LMWH in the thera-
peutic dose (enoxaparin 1 mg/kg twice daily) was maintained.
The brain MRI 3 months later showed encephalomalacia with
resolution of most intraluminal filling defect (Fig. 2). He went
through his second reinduction chemotherapy smoothly with
the concomitant use of LMWH in the prophylactic dose
(enoxaparin 1 mg/kg once daily). Six months after this episode
of SSST, we stopped LMWH after completion of the second
reinduction chemotherapy for nearly complete resolution of
thrombosis demonstrated by brain MRI (Fig. 3) and no clinicalsymptoms or signs related to thrombosis. In the next few days,
he developed a limping gait again, which resolved completely
in 1 week after reinitiation with prophylactic LMWH for 1
more month. He had his further continuation chemotherapy
without similar adverse events. The thrombophilia screening
after discontinuation of LMWH showed protein C 133%,
protein S 66%, antithrombin III (AT-III) 135%, and serum
homocysteine 4.78 umol/L.
Fig. 2. Three months after superior sagittal sinus thrombosis episode. (A)
Axial T2-weighted magnetic resonance imaging shows that the bright-up on
diffusion-weighted images was resolving gradually. (B) Coronal T1-weighted
magnetic resonance imaging reveals resolution of the low-attenuating
thrombus (arrow) within the superior sagittal sinus.
Fig. 3. Six months after superior sagittal sinus thrombosis episode. (A) Axial
T2-weighted magnetic resonance imaging shows encephalomalacic tissue loss
in right anterior high frontal lobe with hemosiderin deposition. (B) Coronal
T1-weighted magnetic resonance imaging reveals nearly total resolution of
superior sagittal sinus thrombosis.
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ALL is the most common malignancy in childhood. With
modern intensive chemotherapy, the overall cure rate in ALL
children is around 80% at the expense of inevitable morbidity,
and possible mortality caused by chemotherapeutic agents,
placement of central venous catheter, and infections related to
ALL treatment.1 Mechanisms for thromboembolic events in
ALL children include the disease itself, exposure to a combi-
nation of steroids and L-asparaginase during induction, andearly insertion of central venous catheters, increased thrombin
generation at diagnosis combined with reduced thrombin
inhibitory capacity, and congenital or acquired prothrombotic
risk factors.2 Venous thrombosis is more frequent in patients
treated for ALL than other malignancies. Most symptomatic
thromboses is related to central venous catheters and may
rarely involve the central nervous venous system.
SSST has been reported to be caused by coagulopathy
following disseminated intravascular coagulation, infection
around the sinus, compression from a tumor, infiltration of
186 T.-Y. Wang et al. / Journal of the Chinese Medical Association 74 (2011) 183e187tumor, and an inherited deficiency of proteins C and S. But
SSST associated with hematological malignancies and L-
asparaginase therapy is rare.
L-Asparaginase is a major component in effective ALL
treatment. Its well-known adverse effects include allergic
reactions, hyperglycemia, pancreatitis, thrombosis, coagulop-
athy, and hyperbilirubinemia. The inhibition of protein
synthesis caused by L-asparaginase is thought to be the basis of
its antineoplastic effect, but it also leads to the depletion of
other plasma proteins involved in coagulation and fibrino-
lysis.3 Vicarioto et al.4 studied fibrinogen and AT-III sequen-
tially during remission induction in 20 ALL children. There
was a significant decrease in the plasma fibrinogen and AT-III
in the first 2 weeks. All parameters gradually returned to
normal after completion of therapy. Impaired thrombin inhi-
bition by anticoagulant deficiency has been proposed as the
main pathogenesis of thombosis in ALL treatment.5 We did
not have the protein C, S, and AT-III data before starting
LMWH because the preemptive usage of LMWH before SSST
was diagnosed by image. But normal thrombophilia screening
after the episode excluded the possibility of congenital causes
of thrombophilia.
Hyperlipidemia is known to be one of the risk factors for
cerebral venous sinus thrombosis. Parsons et al.6 studied the
fasting lipid and lipoprotein levels in 43 ALL children
receiving L-asparaginase and corticosteroid therapy. The mean
peak TG level was significantly higher than the level before
therapy. A striking temporal association between L-aspar-
aginase therapy and hypertriglyceridemia was observed.6
Corticosteroids alone can induce the production of TG-rich
particles and activity of lipoprotein lipase (LPL), which may
prevent extreme rise in TG on corticosteroid therapy.7 But
dramatic decline of LPL activity after L-asparaginase results in
extensive hypertriglyceridemia,7 which may also contribute
to the prothrombotic diathesis. The mechanism by which
L-asparaginase exerts its effect on LPL activity is not known. It
may act by means of a reduction in protein synthesis.7
Why did our patient develop SSST during reinduction
chemotherapy? First, the deranged coagulation secondary to
L-asparaginase and corticosteroid in reinduction chemotherapy
may trigger this event. His preference for greasy and high-
calorie meals led to the high body mass index 18.77, which is
just above the 90e95th percentile of his age- and sex-matched
levels.8 And combination usage of L-asparaginase and corti-
costeroid had further impact on the preexisted hyperlipidemia,
and led to high fasting TG levels 195 mg/dL, which is above
the 95th percentile of his age- and sex-matched levels (TG:
85 mg/dL).9 All these factors contributed to prothrombotic
diathesis and eventually resulted in SSST episode.
Thrombotic events occur because of a combination of
disease-, host- and treatment-related risk factors in ALL
patients. Idiopathic venous thrombosis in childhood is rare.
Apart from a much higher risk in neonates, it is unclear if age
is a risk factor. However, high-risk disease is also associated
with a higher risk of thrombosis. Age-related risk may partly
reflect the effect of ALL-risk stratification and more intensive
treatment.2 Abbott et al.10 found a disproportionate number ofAsian children who developed a central nervous system
thrombosis, although no statistically significant. They sug-
gested race might be examined to see if it is a predisposing
factor for thromboses associated with L-asparaginase with the
expected divergence in inherited polymorphisms.
Chemotherapeutic agents given during induction or inten-
sification courses may influence the hemostasis based on the
observation that more than 90% ALL thrombosis occurred
during the aforementioned courses, not at diagnosis. Aspar-
aginase preparation, length of exposure, and dose may play
a role in ALL thrombosis.2 As to different glucocorticoids, no
statistically significant difference in thrombosis incidence
could be demonstrated.2 Central venous line placement and
inherited thrombophilia increase the thrombotic risk in ALL
patients.2
Because the reported thrombosis incidence varies from 1%
to 36%, various efforts were tried to prevent the thrombosis.
Cohen et al.11 reported neurologic complications associated
with asparaginase-induced hypertriglyceridemia in two ALL
children with extremely high TG levels. They suggested
routine monitoring of fasting TGs levels in all children before
and during asparaginase treatment. Early detection of elevated
levels will enable the introduction of conservative treatment,
and the prevention of further increase of TG to decrease the
risk of potential complication.
Prophylactic fresh frozen plasma and cryoprecipitate had
been administered to prevent thrombotic and hemorrhagic
complications on ALL patients undergoing chemotherapy with
L-asparaginase by Abbott et al.10 They measured AT-III and
fibrinogen level and transfused prophylactic fresh frozen
plasma and cryoprecipitate if AT-III >50 u/mL or fibrinogen
<100 mg/dL. They concluded prophylaxis is unwarranted for
unselected ALL patients.10
The mainstay management for SSST is anticoagulation and
supportive care. Anticoagulation treatment with heparin,
warfarin, urokinase, or LMWH is widely used to treat various
conditions associated with thrombosis. Usage of LMWH
has its advantages of predictable pharmacokinetics, require-
ment of less frequent monitoring, low risk of heparin-induced
thrombocytopenia and osteoporosis, allowance of out-patient
treatment, and less drug-drug interaction with the ALL
chemotherapy.2 Payne and Vora2 recommend that anti-
coagulation with LMWH over warfarin for SSST in the setting
of ALL. Twice daily therapeutic dose (maintaining anti-Xa
level at 0.5e1.0 IU/mL) for 1e3 months is required to treat
SSST. Prophylactic usage with LWMH on once daily dose
(maintaining anti-Xa level at 0.1e0.3 IU/mL) is started from
the day before reexposure to L-asparaginase, and maintained
until 1 week after completing course.2
Because his limping gait developed 3 days after completion
of the second reinduction chemotherapy and discontinuation of
LMWH, and improved greatly after reapplication of prophy-
lactic LMWH,we suggest that the deranged coagulation disorder
may persist for a few more days to weeks even after completion
of L-asparaginase treatment. Further prophylactic usage with
LMWH for a few more weeks after L-asparaginase and steroid
treatment is warranted to minimize occult thromboembolic
187T.-Y. Wang et al. / Journal of the Chinese Medical Association 74 (2011) 183e187events, which may not be well demonstrated in brain imaging
studies.
In conclusion, thromboembolic complications are not
uncommon during the treatment period of ALL, especially
during remission induction period. The rare complication,
SSST, secondary to combination use of L-asparaginase and
dexamethasone should be kept in mind to facilitate timely
diagnosis and treatment, and to avoid further neurological
damage. Anticoagulation therapy with LMWH is effective for
SSST with its advantages of predictable pharmacokinetics and
less drug-drug interaction in the setting of ALL treatment.
Prophylactic usage of LMWH in ALL patients, who had ever
developed SSST, during reexposure to L-asparaginase and
steroid should be adopted and extended to a few weeks after
the completion of reinduction chemotherapy to minimize the
recurrence of SSST.
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